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Abstract: The precise role of adaptive immune responses in the clinical outcome of HCV 
infection is still only partially defined. Recent studies suggest that viral-host cell 
interactions during the acute phase of infection are essential for viral clearance or 
progression into chronic HCV infection. This review focuses on different aspects of the 
adaptive immune responses as determinants of the different outcomes of HCV infection, 
clearance or persistent infection, and outlines current concepts of HCV evasion strategies. 
Unravelling these important mechanisms of virus-host interaction will contribute to the 
development of novel strategies to prevent and control HCV infection. 
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1. Introduction 
Hepatitis C virus (HCV), a member of the Flaviridae family, infects 3% of the population resulting 
in chronic infection in the majority of cases. HCV chronic hepatitis frequently results in progressive 
fibrosis, cirrhosis with an increased risk of hepatocellular carcinoma [1]. These latter complications 
have become leading indications for liver transplantation in developed countries. There is no vaccine 
and the standard of care treatment, a combination of pegylated interferon and ribavirin, is limited by 
resistance in a large fraction of patients, toxicity and high costs. After exposure to HCV, 60 to 80% of 
infected persons develop persistent viremia despite the generation of HCV-specific antibodies and 
HCV-specific cellular immune responses [2,3]. Persistent viremia - detected by polymerase chain 
reaction - remains positive after more than 6 months. Studies of host responses in the course of HCV 
infection have been hampered by the fact that acute HCV infection is asymptomatic in most 
individuals and thus frequently not recognized. Moreover, the chimpanzee is the only 
immunocompetent animal susceptible to HCV infection and there are major differences between HCV 
infection in chimpanzees and in humans. Studies of the host’s immune responses in humans thus rely 
on patient cohorts. Through the availability of serial samples from acute and chronic HCV infected 
patients, insights into the humoral and cellular immune responses in the course of HCV infection could 
be gained in the past years. 
The present review focuses on different aspects of the adaptive immune responses as determinants of 
the different outcomes of HCV infection, clearance or persistent infection, and outlines current 
concepts of HCV evasion strategies.  
2. The humoral responses to HCV infection 
Neutralizing antibodies are generally an important mechanism for control of initial viremia and 
protection from re-infection in viral infections. However, the role of the humoral immune response in 
the clearance of HCV infection has been questioned for a long time. While anti-HCV antibodies can 
easily be detected in the course of HCV infection by commercially available antibody assays 
approximately 50 to 60 days after HCV infection [4], these tests only attest a humoral immune 
response to HCV proteins but they do not evaluate the neutralizing ability of these antibodies. The 
ability of antibodies to neutralize HCV can solely be evaluated using relevant model systems. 
Determining the relative role of antibodies in the course of HCV infection has long been hampered 
by the absence of a convenient model system for evaluating the neutralizing activity of anti-HCV 
antibodies. HCV infects only humans and chimpanzees and for a long time the chimpanzee represented 
the only validated animal model for the study of HCV (reviewed in [5]). Over the past years, the 
development of sensitive and robust in vitro neutralization assays based on human hepatoma cell lines 
and HCV pseudotyped particles[6-8], HCV-like particles [9-11] and recombinant cell culture-derived 
HCV (HCVcc) [12-19] then allowed to conveniently study the role of neutralizing antibodies in acute 
and chronic HCV infection. Moreover, the recent development of an in vivo model based on 
immunodeficient mice repopulated with human livers, the uPA-SCID mice [20], enabled investigators 
for the first time to determine the role of antibodies in HCV infection in a small animal model [21,22].  
Early studies investigating immune responses in chimpanzees and humans suggested that HCV 
clearance could occur in the absence of neutralizing antibodies or that antibody responses alone are not Viruses 2009, 1                                       
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sufficient to eradicate HCV in the majority of cases [23-27]. Moreover, individuals who cleared HCV 
are not protected against re-infection, although chimpanzees and individuals who have cleared HCV 
seem to be less likely to develop chronic infection after re-exposure [28-30]. Since the development of 
novel model systems for the study of HCV infection and neutralization in vitro, the availability of 
sequential serum samples from homogenous patient cohorts, well-defined viral inoculum and viral 
surrogate ligands used for neutralization assays, isolate-specific neutralizing antibodies have been 
detected in acutely HCV infected individuals who subsequently cleared viral infection. In contrast, the 
humoral immune responses seem to be delayed in patients developing chronic HCV infection, thereby 
allowing the virus to escape the host’s immune surveillance.  
2.1. Neutralizing antibodies and control of viral infection  
Since the availability of several in vitro HCV model systems [8,9,12-14], considerable progress has 
been made in understanding how HCV enters into host cells and how antibodies may neutralize this 
process. Binding and entry of HCV is believed to be a complex process involving both viral and 
cellular factors. The essential viral factors are the HCV envelope glycoproteins E1 and E2 which have 
been demonstrated to directly interact with cellular factors and to trigger conformational changes 
necessary to initiate infection. Several cellular factors have been identified to mediate viral attachment 
and entry, such as CD81, scavenger receptor class B type I (SR-BI), members of the claudin family 
and occludin [31-41]. HCV envelope glycoprotein E2 has been demonstrated to directly interact with 
CD81 and SR-BI [31,32] but the interaction of HCV envelope glycoproteins with the other host entry 
factors is still elusive [36,38]. As the HCV envelope glycoprotein E1 and E2 interaction with host cell 
factors is mandatory to initiate productive infection, it is an important target for virus neutralization.  
Using retroviral pseudoparticles bearing HCV envelope glycoproteins (HCVpp), neutralizing 
antibodies have been detected in patients with acute and chronic HCV infection. The association 
between the induction of neutralizing antibodies for resolution of infection during acute HCV infection 
has been demonstrated using well defined viral inoculum and autologous surrogate ligands [42-44]. 
Lavillette et al. and Pestka et al. have shown that neutralizing antibodies are induced in the early phase 
of infection by patients who subsequently control [42] or resolve [43] viral infection. In hemodialysis 
patients with nosocomial acquired HCV infection, strong neutralizing responses correlated with 
decrease in viremia and control of HCV replication whereas absent neutralizing response associated 
with persistent high viremia and failure to control HCV infection [42]. Moreover, in an accidental 
single-source outbreak of hepatitis C in pregnant women, viral clearance was associated with the rapid 
induction of high-titer and cross-neutralizing antibodies in the acute phase of infection while chronic 
HCV infection was characterized by a complete absence or reduced capacity to neutralize the 
transmitted virus as well as heterologous viruses in the early phase of infection [43]. These results 
suggest that a strong early broad neutralizing antibody response may contribute to resolution of HCV 
in the acute phase of infection while delayed induction of neutralizing antibodies may contribute to 
development of chronic HCV infection (Figure 1).  Viruses 2009, 1                                       
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Figure 1. Viral escape from neutralizing antibody responses. In infected individuals, HCV 
exists as a quasispecies, i.e., a pool of constantly changing, distinct but related genomic 
variants.  Resolving HCV infection is associated with a relatively stable pool of viral 
variants and the early induction of high-titer cross-neutralizing antibodies. Chronic HCV 
infection is correlated with diversification of the quasispecies population associated with a 
delayed induction of cross-neutralizing antibodies allowing viral escape from the host 
humoral responses. 
Control of
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2.2. Viral escape from neutralizing antibodies 
As HCV has evolved several mechanisms to escape from the host immune responses (reviewed in 
[45]), neutralizing antibodies and HCV co-exist during chronic infection in patients who did not mount 
efficient immune responses able to clear the virus during acute infection (Figure 1). Viral escape from 
antibody-mediated neutralization has been shown to occur on several levels and in line to reports of 
other viruses, a combination of different mechanisms may also apply to HCV. These include (1) the 
high variability of the HCV genome and limited induction of cross-neutralization antibodies, (2) 
induction of antibodies interfering with neutralizing antibodies, (3) the association of HCV with serum 
factors such as low-density lipoproteins (LDL) and very low density lipoproteins (VLDL), (4) the 
interplay of HCV glycoproteins with high-density liporoteins (HDL), (5) the shielding of neutralizing 
epitopes by glycosylation of defined amino acids of envelope glycoproteins, and (6) direct cell-to-cell 
transfer of the virus. As these mechanisms have been reviewed elsewhere [45], this review will focus 
on recent studies demonstrating both in vitro and in vivo viral adaptations leading to escape from 
neutralizing antibodies. 
Using the state-of-the-art HCV cell culture model, Zhong et al. investigated adaptation of HCV in 
vitro [46]. The authors demonstrated that HCV can establish persistent infection in vitro, which lead to 
the selection of viral and cellular variants that favour the survival of both the virus and the host [46]. 
The virus acquired increased specific infectivity whereas the host cell became resistant to HCV 
infection. This resistance may be due to down-regulation of HCV entry factor expression or a defect in 
HCV replication or a combination of these mechanisms [46]. While substantial progress in Viruses 2009, 1                                       
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understanding the HCV life cycle has been made, the interplay between host cell entry factors, HCV 
envelope glycoproteins and neutralizing antibodies is only about to be investigated. Recent evidence 
suggests that neutralizing antibodies isolated from chronic HCV patients interfere with entry steps that 
are closely linked to the interaction of HCV with SR-BI and CD81 [15,47]. Evasion from antibody-
mediated neutralization through decreased receptor binding has been reported for viruses such as HIV-
1 [48]. This mechanism seems also to apply to HCV. The cell culture-adapted mutation G451R 
initially described by Zhong et al. [46] has been shown to be less dependent on SR-BI and CD81 on 
the entry level [16]. Moreover, this mutant demonstrated an increased binding to CD81 and CD81 
mimics while being more sensitive to neutralizing antibodies [16].  
In chronic HCV infected patients, HCV coexists with anti-HCV antibodies. It is thus most interesting 
to understand how HCV evolves in the presence of neutralizing antibodies. A recent study addressed 
this important question by investigating in vitro HCV escape mutants through multiple rounds of 
selection by the well-described anti-E2 monoclonal antibody AP33 [49]. The authors described an in 
vitro escape mutation HCV N415Y that lowered viral fitness probably by affecting viral entry but 
without affecting binding to CD81 [49] suggesting that mutations modulating interaction with host cell 
factors other than CD81 may contribute to escape of HCV from neutralizing antibodies. Taken 
together, these studies show that in cell culture, mutations within the HCV envelope glycoproteins 
arise that modulate viral entry and neutralization by anti-HCV antibodies. 
As described above, resolution of infection appears to require rapid, vigourous and multi-specific 
antiviral host immune responses [43,45,50,51]. Patients who subsequently develop chronic infection 
have been shown to develop a delayed and inefficient neutralizing antibody response [43] allowing 
HCV infection to persist for lifetime despite the presence of neutralizing antibodies. It is believed that 
the adaptive immune system exerts constant pressure on the virus thereby leading to the emergence of 
HCV escape mutants. However, little is known about the role of neutralizing antibodies in driving 
HCV sequence evolution in the course of infection. A recent study addressed this important question 
and provided insights into the time-course of induction of neutralizing antibodies and viral escape 
from neutralizing responses in a cohort of young intravenous drug users [44]. Studying autologous 
humoral immune responses in individual subjects, the authors demonstrate that during acute HCV 
infection, earlier HCV variants were neutralized by autologous plasma samples prior to neutralization 
of later HCV variants, similar to what has been shown in a chronic HCV patient [52], suggesting that 
neutralizing antibodies are responsible for envelope sequence changes over time [44]. In line with 
previous results obtained in a cohort of patients from a single-source HCV outbreak [43], this study 
demonstrated an association of high-titer neutralizing antibodies and spontaneous viral clearance 
whereas persistent HCV infection was associated with low-titer or absent neutralizing antibodies 
during the acute phase [44]. These data suggest that humoral immune response pressure drives HCV 
envelope glycoprotein sequence evolution resulting either in effective clearance of circulating viral 
variants and resolution of infection or emergence of viral escape variants and progression into chronic 
infection. Analysis of sequence substitutions that occurred in HCV envelope glycoproteins during 
acute infection were monitored throughout E1E2 but most of them were located in the HVR1 region 
[44]. Mapping of amino acid substitutions involved in escape from neutralizing antibodies showed that 
significant loss of sensitivity to neutralizing antibodies could be attributed to 3 HVR1 mutations 
(K384T, K408R and S405P) [44]. A similar time-course study had previously been conducted in the Viruses 2009, 1                                       
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well-characterized chronic HCV patient H [52]. Consistent with the results obtained during the acute 
phase study described above [44], von Hahn et al. demonstrated that throughout the course of this 
chronic HCV infection, the patient’s antibodies lagged behind the rapidly evolving viral variants, i.e. 
they were able to neutralize HCV strains that had been circulating several months or years before but 
not the present or future viral variants of the patient [47,52]. This raised the question of the 
mechanisms underlying escape of such quasispecies from neutralizing antibodies. By investigating the 
interaction of these neutralizing antibody-escape variants and HCV host cell factors, Keck et al. 
described a single viral variant from this patient that was characterized by reduced infectivity, 
diminished CD81 binding and resistance to a panel of anti-E2 antibodies (domain B antibodies and 
AP33). Thus by escaping from neutralizing antibodies, HCV seems to loose in infectivity due to lower 
binding to CD81. It is worth noting that several mutations within E2 but outside the anti-E2 epitopes 
as well as the CD81 binding regions may account for escape from these neutralizing antibodies as site-
directed mutations were able to restore sensitivity to neutralizing antibodies and CD81 dependency 
[47]. The most important mutations responsible for reduced infectivity and binding to CD81 were 
S501N and V506A, suggesting that mutation of theses amino acids affect the conformation of E2 
necessary for interaction with CD81 [47]. However, these mutations did not account for escape from 
humoral responses. Interestingly, an additional mutation at residue 444 is necessary in order to lead to 
complete escape from neutralizing antibodies – this additional mutation at position 444 seems to 
negatively modulate antibody-mediated neutralization in concert with the mutations at residues 501 
and 506 [47]. 
Recently, Zhang et al. described an additional escape mechanism whereby the presence of non 
neutralizing antibodies interferes with the function of neutralizing antibodies, resulting in the reduction 
or blockage of their effect [53,54]. Two epitopes within a short segment of E2 were mapped: epitope I, 
at amino acids 412-419, and epitope II, at amino acids 434-446. Epitope I has been recognized as an 
important neutralization site, while epitope II interfered with antibody to epitope I inhibiting 
neutralization of the virus [53]. Epitope I- and epitope II- specific antibodies were detected in plasma 
from chronically HCV-infected patients. Kinetic studies in patient H revealed that antibody to epitope 
II appeared within 51 days of infection, while antibody to epitope I was not detectable until day 643. 
Interestingly, by absorbing out antibody to epitope II, neutralizing activity of plasma was enhanced 
and broadened to include additional genotypes of HCV [54].  
3. T cell responses to HCV infection 
The majority of primary infections are asymptomatic and often unrecognized. Thus, studies of T cell 
immune responses during acute HCV infection have only been possible in experimentally infected 
chimpanzees or individuals with occupational needle stick exposure or IVDU involved in 
epidemiological follow-up for which the time of contamination is documented. A large body of 
evidence suggests that a strong, multispecific and long-lasting T-cell immune response appears to be 
important for control of viral infection (reviewed in [27,55]).  
Three types of T cell-mediated responses can be raised against HCV [27,55]. First, an efficient 
primary immune response during the acute phase, leading to a resolved HCV infection and 
maintenance of an efficient CD4 and CD8 memory. This immune response is sustained and targets Viruses 2009, 1                                       
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multiple viral proteins, especially during the acute phase of the response. Second an efficient but 
transient primary immune response, leading to partial control of the infection, but ultimately CD4 
memory cells are absent while CD8 memory cells are present at a variable level, leading to chronic 
infection. Third, a lack of efficient primary immune response, leading to chronic infection. Memory 
CD4 and CD8 memory cells are less frequent, functionally impaired and target less viral proteins than 
in patients with resolved infection. 
This review will focus on cellular and viral factors that may influence the efficiency and 
maintenance of primary T cell mediated immune responses including incomplete differentiation of 
effector and memory T cell populations, immune exhaustion resulting from persistent high viral loads 
mediated by programmed death-1 (PD-1) protein signalling, suppression by regulatory T (Treg) cells 
and immune escape mutations. 
3.1. T cell immune responses and control of viral infection  
In humans and chimpanzees a self-limited course of acute hepatitis C is associated with vigorous 
CD4+ and CD8+ T cell responses targeting multiple HCV regions and with intrahepatic production of 
IFN-γ [23,24,51,56,57]. In a study of five healthcare workers the only subject able to clear acute HCV 
infection mounted an early, vigorous and sustained CD4+and CD8+ T cell response [51]. A study 
using IFN-γ enzyme-linked immmunospot (ELISPOT) and human histocompatibility leukocyte 
antigen (HLA) peptide tetramer assays, revealed that at the earliest time points of acute infection 
highly activated CTL populations are observed that temporarily fail to secrete IFN- γ, a “stunned” 
phenotype, from which they recovered as viremia declined [24]. Resolution of acute infection was 
associated with T cell recovery of an activated phenotype and the ability to produce IFN-γ [24].  
The non structural proteins have been described to be preferentially targeted by the CD4 +T cell 
responses in those who clear infection [58-61]. One of the most recent cross-sectional study of 
proliferative responses in 22 subjects with resolved infection and 23 with chronic infection showed 
that at least three of the six non-structural proteins were targeted by all subjects who had cleared HCV 
infection, with less frequent responses against the core protein and the variable regions of the envelope 
protein [58]. In all studies, one or more epitopes on NS3 were targeted, suggesting that epitopes in this 
protein may be immunodominant [50,59,62,63]. This observation is supported by a study examining 
IFN-γ ELISpot responses to three peptide pools spanning NS3 which showed that all subjects who had 
recovered from infection mounted a strong CD4+ response to all three pools [62]. Similar to CD4+ T 
cell responses against HCV, it has been suggested that the breadth of the CD8+ T cell response is 
associated with clearance in both humans and chimpanzees [23,24,64]. In a recent study of 17 patients 
with acute HCV leading to persistence and 14 with primary infections resulting in clearance [65] this 
notion was corroborated: total HCV-specific specific CD4+ and CD8+ T-cell responses were 
examined and functional T-cell thresholds that predict recovery identified. The likelihood of recovery 
was considerably greater in individual subjects exceeding these thresholds ; for example if five or 
more HCV peptides pools (or 15% of the HCV genome) are targeted by CD4+ T cells early after 
infection the chance of recovery was more than seven times higher than if this threshold was not 
achieved. Similarly it has been shown by logistic regression analysis that patients demonstrating HCV-
specific IFN- γ-producing CTL responses to at least two HCV peptides pools were statistically more Viruses 2009, 1                                       
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likely to contain HCV infection than patients demonstrating responses to only one or none of the HCV 
peptide pools. 
The kinetics of onset and the durability of the cellular immune responses may also be an important 
determinant of outcome. Both human and chimpanzee studies have demonstrated a CD4+ response 
that is initially effective with a subsequent rebound in viremia and progression to chronic infection 
[23,51]. A prospective study of 20 subjects with acute infection showed that the number of Th1 
cytokine–producing CD4+ cells was higher in the first 12 weeks after disease onset in the subjects 
with rapid viral clearance compared to those with only transient or no control of viremia [63]. The 
strongest CD4+ T cell response to HCV infection has been shown to occur within the first six months 
after infection regardless of outcome [60,63,64,66]. Thus, it appears that a successful CD4+ T cell 
response needs to develop early and also to be sustained to achieve viral clearance [67].  
Smyk-Pearson et al. studied the relative importance of CD4 help in spontaneous recovery in acute 
HCV infection and demonstrated that [65] the presence of HCV-specific cytotoxic T lymphocytes – 
able to proliferate, exhibit cytotoxicity and produce IFN – γ - did not ensure recovery, but whether 
these CTLs were primed in the presence or absence of T-cell help (HCV-specific IL-2 production) was 
a critical determinant. This is also strongly supported by CD4-depletion studies in the chimpanzee 
model of infection [68]. Helper CD4+ T cells are important through the maintenance of the effector 
functions of cytotoxic CD8+ T cells. This is mediated both by activation of co-stimulatory pathways 
and via the production of cytokines notably IL-2 and IFN – γ [69]. Only patients able to finally control 
infection show maturation of CD8 memory sustained by progressive expansion of CD127+ CD8 cells 
[67]. 
The cellular immunity appears to persist for many years after resolution of infection in chimpanzees 
and humans [62,66,70]. After viral clearance, memory T cells maintain over decades and can mediate 
protective immunity in spontaneously HCV-recovered chimpanzees following re-challenge with 
homologous and heterologous HCV [29,30,71]. The rapid control of HCV viremia following re-
challenge was found to be associated with early anamnestic HCV-specific CD4+ and CD8+ T cell 
responses, including memory CD4+ T cell responses [68,72-74]. However, recent studies in 
chimpanzees contradict the early studies [75]. Thus, a chimpanzee that had previously demonstrated 
protective immunity following multiple re-challenges with heterologous viruses became chronically 
infected when re-exposed to the virus originally inoculated into the animal [75]. These findings are 
supported by evidence that chimpanzees tend to mount weak humoral responses to HCV envelope 
glycoprotein E2. Indeed, a lower percentage of HCV-inoculated chimpanzees develop detectable 
antibodies to envelope glycoproteins E1 (22%) and E2 (15%) as compared to humans [76]. 
3.2. Mechanisms of T cell failure 
In contrast to acute resolving HCV infection, persisting acute HCV infection is associated with a 
weak and only monospecific CD4+ T cell responses [77]. Regarding the role of CD8+ T cells, recent 
studies in humans demonstrated that even strong CD8+ T cell responses in the acute phase of infection 
may not be adequate to prevent progression to chronicity [64,67,78]. Urbani et al. showed that at 
clinical onset, CD8 responses are similarly weak and narrowly focused in both self-limited and 
chronically evolving infections [67]. At this stage, CD4 responses are deeply impaired in patients with Viruses 2009, 1                                       
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a chronic outcome as they are weak and of narrow specificity, unlike the strong, broad and T helper 1-
oriented CD4 responses associated with resolving infections.  
An important issue is to determine what signals allow to sustain memory cells. In murine models of 
viral infections, an acute viral infection is generally associated with a high expansion of effector cells 
that differentiate from naïve cells [79]. This expansion phase is followed by a contraction phase 
leading to the elimination of ~90% of effector cells, while the remaining effector cells differentiate 
into long-lived protective memory cells. In human, the differentiation pathways of effector and 
memory cells may not be similar, and effector cells may be replenished from memory cells. Therefore, 
it is of crucial importance to identify the mechanisms that allow some patients to maintain HCV-
specific memory, while some other are inefficient in controlling the infection. Some key factors may 
be IL-7 and IL-15, that have been demonstrated to be involved in the induction and homeostasis of 
CD8 memory cells [80]. IL-7Rα expression is decreased upon T-cell activation: during acute viral 
infections, the expression of IL-7Rα by viral antigen-specific T cells is transiently decreased 
[69,81,82] and recovers at late time points after infection when an  efficient memory response is 
obtained [69,83] while IL-7Rα expression remains at a low level in the setting of inefficient memory 
responses in chronically infected subjects [81]. IL-7Rαhigh expression may therefore allow identifying 
cells that will give rise to memory cells, at least in the setting of infections that lead to an 
inflammatory response [69], but not when antigen is presented in a non inflammatory context [84]. 
Indeed, IL-7Rα expression follows an IL-7-independent program of expression [85] that may be 
controlled by the level of inflammation [84,85] or the strength of TCR signalling or viral load at time 
of antigen presentation [82]. IL-15 is also involved in survival of memory cells, especially when IL-7 
signalling is present in limiting conditions [69,80]. Indeed, IL-15 is critical for memory cell survival in 
normal animals, where IL-7 may be limiting due to competition with naïve cells, which use IL-7, but 
not IL-15, signalling for homeostatic proliferation [86-90]. The CD4-mediated production of another 
cytokine of the same family, IL-21, has been shown recently to be of crucial importance in avoiding 
deletion and maintaining memory responses of CD8 T cells in the murine model of LCMV infection 
[91-93]. Whether IL-21 is also critically involved in maintaining memory HCV-specific memory in 
humans remains to be determined.  
In the context of HCV infection, expression of IL-7Rα by total CD4 and CD8 T cells as well as by 
HCV-specific cells has been reported to be reduced in the blood of patients with chronic infection as 
compared with patients with resolved infection [94], although such decreased IL-7Rα expression by 
HCV-specific memory cells remains controversial [95,96]. IL-7Rα expression is even more decreased 
in liver CD8+ lymphocytes than in blood lymphocytes from chronic patients [95]. Interestingly, 
patients with acute infection who subsequently resolved the infection had higher baseline values of IL-
7Rα expression (i.e. at time of acute infection) than patients with acute infection who subsequently 
evolved toward chronic infection [94]. However, this picture may be even more complex, as two 
profiles of IL-7Rα expression have been observed in chronic HCV patients: most patients have 
exhausted HCV-specific CD8+ T cells, with low IL-7Rα expression, low proliferative and IFN- 
secretion potential, but some patients have HCV-specific T cells that express high levels of IL-7Rα 
expression and maintain an efficient proliferative and IFN- secretion potential, similar to HCV-
specific T cells from patients who resolved their infection [96].  Viruses 2009, 1                                       
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In the chronic phase, virus specific CD4+ and CD8+ T cell responses are also detectable. However 
HCV-specific CD4+ and CD8+ T cells isolated from chronically infected patients usually display 
functional and maturation defects including reduced cytotoxic potential, reduced secretion of Th1-type 
cytokines and a reduced proliferative capacity in response to ex vivo antigenic stimulation [57,97,98]. 
CD8+ T cell exhaustion such as observed during chronic HCV infection is described in different 
murine models of persistent infection with highly replicative viruses and may result from deficient 
CD4+ T cell help (reviewed in [99]). Ulsenheimer et al. have described functionally altered HCV 
specific CD4+ T cells in acute and chronic hepatitis C [100]. CD8+T cell exhaustion and persistent 
infection are more likely to develop when CD4+ T cells help is lacking or lost (Figure 2). Helper 
CD4+ T cells activate or license dendritic cells to optimally prime CD8+ T cells, recognition of 
antigen on the same antigen-presenting cell by CD4+ and CD8+ T cells is likely to be a key feature of 
antigen-specific T cell help. Thus the failure of CD4+HCV specific T cells may limit CD8+ T cells 
opportunities of priming by fully activated HCV antigen- loaded DC [27]. 
Another mechanism that may be involved in secondary T cell failure of HCV-specific CD4+ and 
CD8+ T cells in chronic HCV infection is signalling through programmed death 1 receptor (PD-1) 
(Figure 2). Down regulation of virus –specific T-cell responses via signalling through PD-1 on T cells 
has been linked with virus-specific T-cell deficiency during chronic viral infections in a murine model 
and in humans [101,102]. Several recent studies have demonstrated high expression levels of PD-1 in 
HCV-specific CD8+ T cells in patients with persistent HCV infection [55,95,103,104]. HCV-specific 
T cells that demonstrated increased expression of PD-1 on their surface exhibited impaired IFN- 
production, cytotoxic activity and proliferative potential in response to ex vivo HCV antigen 
stimulation [55,95,103]. Such impaired functional properties could be reversed by in vitro blockade of 
PD-1 interaction with its ligand PD-ligand 1 (PD-L1), demonstrating a causal relationship between 
PD-1 expression and exhaustion [95,103]. 
Different T-cell subsets with suppressive functions have been described (Figure 2). Among these, 
CD4+ CD25+ FoxP3+ regulatory T (Treg) cells have been involved in the control of auto-immunity 
and immune responses, through various mechanisms including the inhibition of APC maturation and 
T-cell activation (reviewed in [105]). An increased frequency of Treg cells has been observed in 
patients with chronic HCV infection compared to individuals who spontaneously resolved HCV 
infection [106-109]. However, a recent study in chimpanzees showed no difference in the frequency of 
Treg cells and the extent of suppression irrespective of the outcome of the infection [110]. Evidence 
against a role for Treg in promoting the development of chronic infection was recently reported in a 
prospective study of 27 acutely infected subjects. This study showed that there was no significant 
difference in the proportion of CD4+CD25
high T cells in the peripheral blood at baseline between the 
15 subjects who developed chronic infection and the 12 subjects that subsequently cleared the 
infection [65]. The frequency for both groups was higher than in healthy controls and did not vary over 
time. Further studies are thus required to define the potential role of Treg in the outcome of primary 
HCV infection. Viruses 2009, 1                                       
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Figure 2. Examples of mechanisms resulting in impairment of T cell responses leading to 
chronic HCV infection. Chronic HCV infection is associated with impaired CD8+ T cell 
responses including reduced cytotoxic potential, reduced secretion of Th1 type cytokines 
and reduced proliferative capacity in response to ex vivo antigenic stimulation. Four 
possible mechanisms of T cell response failure are shown here: (1) viral escape with 
mutations in HLA restricted epitopes impairing antigen recognition, (2) loss of functional 
CD4+ T cell responses, (3) overexpression of PD1 in CD8+ T cells; when PD1 binds to its 
ligand PD-ligand 1 (PD-L1), which is preferentially expressed by virus-infected cells, an 
inhibitory signal is transmitted to CD8+ T cells, resulting in blocking of the T cell 
receptor-mediated activation signal, (4) induction of regulatory T cells. Arrows with single 
line indicate functional interactions while arrows with double lines indicate cell 
differentiation.  
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Viral escape from CD8+T cells is another important mechanism of T cell response failure in 
patients developing persistent infection [111-115] (Figure 2). Studies in humans and chimpanzees have 
shown that mutations in HLA class I restricted epitopes targeted by CD8+ T cells, occur early in HCV 
infection and are associated with persistence [116,117]. The role of HLA alleles in determining the 
outcome of HCV infection has been recently studied in an Irish cohort of women accidentally infected 
with HCV [118]. The HLA class I alleles A3, B27 and Cw*01 were associated with viral clearance 
whereas B8 was associated with viral persistence indicating that the host genetic background is an 
important variable that can influence infection outcome [118]. Interestingly stable cytotoxic T cell 
escape mutations have been linked to maintenance of viral fitness [119]. According to these authors, 
these observations elucidate potential mechanism by which viral persistence is established. Whereas 
consequences of stable integration of escape mutations into viral genomes are not clear, it is possible 
that epitopes presented by the most prevalent MHC class I molecules in human population will 
eventually be lost or become less dominant [120].  Viruses 2009, 1                                       
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4. Conclusions and perspectives 
In the last few years, considerable progress has been made in studying humoral and cellular 
responses in the course of HCV infection. While the role of neutralizing antibodies in outcome of 
HCV infection has long been questioned, the development of novel and convenient model systems for 
HCV infection showed an association between strong and early neutralizing responses and viral 
clearance. A self-limited course of acute hepatitis C is associated with a vigorous CD4+ and CD8+ T 
cell response targeting multiple HCV regions and with intrahepatic production of IFN-γ 
[23,24,51,56,57]. Clearance of HCV is thus probably mediated by a coordinated action of cellular and 
neutralizing immune responses. Only rare studies analyzed in parallel both humoral and cellular 
immune responses in the course of HCV infection [52]. Von Hahn et al. demonstrated that during 
chronic HCV infection in patient H, HCV is subjected to selection pressure from humoral and cellular 
immune responses resulting in the continuous generation of escape variants [52]. These data 
underscore that neutralizing antibody responses and cellular antiviral immunity are frequently 
impaired due to both viral and host factors leading to viral escape from the host’s immune surveillance 
and development of chronic infection. 
Novel insights into the mechanisms underlying successful immune responses against HCV in 
individuals spontaneously clearing infection and elucidation of escape mechanisms from adaptive 
immune responses in chronic HCV patients will be essential for an improved understanding of HCV 
pathogenesis. Unravelling these important mechanisms of virus-host interactions will contribute to the 
development of novel strategies to prevent and control HCV infection.  
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